Comparing AtriCure (ATRC) and Steris (STE)
AtriCure (NASDAQ: ATRC) and Steris (NYSE:STE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.
This table compares AtriCure and Steris’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and recommmendations for AtriCure and Steris, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AtriCure presently has a consensus target price of $25.00, suggesting a potential upside of 39.20%. Steris has a consensus target price of $72.33, suggesting a potential downside of 18.22%. Given AtriCure’s stronger consensus rating and higher probable upside, equities analysts clearly believe AtriCure is more favorable than Steris.
Insider & Institutional Ownership
86.2% of AtriCure shares are owned by institutional investors. Comparatively, 89.5% of Steris shares are owned by institutional investors. 10.0% of AtriCure shares are owned by insiders. Comparatively, 2.6% of Steris shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Volatility and Risk
AtriCure has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Steris has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.
Earnings & Valuation
This table compares AtriCure and Steris’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AtriCure||$155.11 million||3.99||-$33.33 million||($1.02)||-17.61|
|Steris||$2.61 billion||2.88||$109.96 million||$1.68||52.65|
Steris has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Steris, indicating that it is currently the more affordable of the two stocks.
Steris pays an annual dividend of $1.24 per share and has a dividend yield of 1.4%. AtriCure does not pay a dividend. Steris pays out 73.8% of its earnings in the form of a dividend. AtriCure has increased its dividend for 7 consecutive years.
Steris beats AtriCure on 9 of the 16 factors compared between the two stocks.
AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart’s left atrial appendage (LAA).
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others. Its Corporate and other segment includes the Defense and Industrial business unit.
Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.